calcifediol Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Calcifediol (25-Hydroxyvitamin D3 or 25-hydroxycholecalciferol) is a biologically active vitamin D3 metabolite. It is concluded that the liver is the major if not the only physiologic site of hydroxylation of vitamin D3 into calcifediol. Calcifediol is a prohormone of the active form of vitamin D3, calcitriol (1,25-dihydroxyvitamin D3). Calcifediol is converted to calcitriol by cytochrome P450 27B1 (CYP27B1), also called 1-alpha hydroxylase, primarily in the kidney. Calcitriol binds to the vitamin D receptor in target tissues and activates vitamin D responsive pathways that result in increased intestinal absorption of calcium and phosphorus and reduced parathyroid hormone synthesis. RAYALDEE (calcifediol) extended-release capsules is indicated for the treatment of secondary hyperparathyroidism in adult patients with stage 3 or 4 chronic kidney disease.   NCATS

Chemistry

  • SMILES: C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(=C\C=C/3\C[C@@H](O)CCC3=C)\CCC[C@]12C
  • InChIKey: JWUBBDSIWDLEOM-DTOXIADCSA-N
  • Mol. Mass: 400.65
  • ALogP: 6.73
  • ChEMBL Molecules:
    None  
    calcifediol  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$22.2793 - $36.6193
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

25-hydroxycholecalciferol | 25-hydroxy vitamin d | 25-hydroxy vitamin d3 | 25-hydroxyvitamin d3 | (3s,5z,7e)-9,10-secocholesta-5,7,10-triene-3,25-diol | (3β,5z,7e)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol | (5z,7e)-(3s)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol | calcidiol | calcifediol | calcifédiol | calcifediol anhydrous | calcifediolum | calcifidiol | calderol | u-32070e

Organizations (45)

Research & Development (44)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (26)

Approved Indications (4)


 

Chronic Kidney Disease-Mineral and Bone Disorder (approved 1980)

Hyperparathyroidism, Secondary (approved 2016)

Hypocalcemia (approved 1980)

Hypophosphatemia (approved 1980)

Experimental Indications - Clinical Trial Phases 1-4 (24)


 

Accidental Falls (Phase 2)

Acute Kidney Injury (Phase 2)

Asthma (Phase 4)

Cardiovascular Diseases (Phase 4)

Chronic Kidney Disease-Mineral and Bone Disorder (Phase 4)

Coronavirus (Phase 2)

COVID-19 (Phase 2)

Critical Illness (Phase 2)

Cytokine Release Syndrome (Phase 2)

Diabetes Mellitus, Type 2 (Phase 3)

Frail Elderly (Phase 1)

Healthy Volunteers (Phase 1)

Hip Fractures (Phase 4)

Hyperparathyroidism (Phase 4)

Hyperparathyroidism, Secondary (Phase 4)

Kidney Failure, Chronic (Phase 4)

Malabsorption Syndromes (Phase 1)

Myocardial Infarction (Phase 3)

Osteomalacia (Phase 4)

Osteoporosis (Phase 3)

Prostatic Neoplasms (Phase 2)

Severe Acute Respiratory Syndrome (Phase 2)

Sleep Apnea, Obstructive (Phase 2)

Vitamin D Deficiency (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 27
  • # of Trial Organizations: 44

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue